Results of a multicenter study of 129 women with advanced breast cancer show that a blood test that spots cancer-linked DNA correctly predicted that most of those patients with higher levels of the tumor markers died significantly earlier than those with lower levels.
Mark Burkard was named director of University of Iowa Health Care Holden Comprehensive Cancer Center.
